WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader bri ...

Core Insights - Crinetics Pharmaceuticals, Inc. will participate in two upcoming investor conferences, providing opportunities for 1x1 meetings with management [1][2] - The company focuses on transforming the treatment of endocrine diseases and related tumors through innovative therapies [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for acromegaly, with additional programs in development for various endocrine conditions [4] Group 1: Upcoming Events - Crinetics will attend the TD Cowen 46 Annual Health Care Conference in Boston on March 4, 2026, with a fireside chat scheduled for 1:50 p.m. Eastern Time [1] - Management will also be available for 1x1 meetings on March 4, 2026, and at the Leerink Annual Global Healthcare Conference in Miami on March 11, 2026 [1] Group 2: Company Overview - Crinetics Pharmaceuticals is dedicated to discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) [3] - The company has a pipeline of over 10 disclosed programs, including late-stage candidates for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs address various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 4:30 p.m. ET to discuss the results and provide a business update [1]. Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [4]. - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [4]. Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [5]. - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [5]. - The company has a deep pipeline of over 10 disclosed programs, including late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate for treating SST2 expressing neuroendocrine tumors and other solid tumors [5]. - Additional discovery programs target various endocrine conditions such as Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [5].

Core Insights - Crinetics Pharmaceuticals has initiated the BALANCE-CAH Phase 2/3 trial for atumelnant, a novel ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) in children and adolescents [1][2] Group 1: Study Overview - The BALANCE-CAH trial is designed to evaluate the safety, efficacy, and pharmacokinetics of atumelnant in pediatric patients with CAH, addressing a significant unmet medical need [2][3] - The study consists of three parts: Part A is a Phase 2 open-label dose-ranging study, Part B is a Phase 3 double-blind randomized placebo-controlled study, and Part C is an open-label extension [3] Group 2: Atumelnant Details - Atumelnant is the first and only small molecule ACTH receptor antagonist in late-stage clinical development, specifically targeting the melanocortin type 2 receptor (MC2R) to block excess androgen production [2][4] - Preclinical studies have shown that atumelnant has a strong binding affinity for MC2R and has demonstrated significant reductions in key CAH biomarkers, indicating its potential to transform care for individuals with CAH [4] Group 3: Company Background - Crinetics Pharmaceuticals focuses on developing novel therapies for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [5] - The company’s lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved for adults with acromegaly, and it has a robust pipeline of over 10 programs, including atumelnant [6]

Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

Core Insights - Crinetics Pharmaceuticals, Inc. is preparing to host a conference call on January 5, 2026, to discuss the commercialization of PALSONIFY, the first FDA-approved oral treatment for acromegaly, and to share results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia [1][6] Group 1: Company Overview - Crinetics focuses on developing treatments for endocrine diseases, utilizing small molecules that target G-protein coupled receptors (GPCRs) [2] - The company's pipeline includes atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as CRN09682 for SST2 expressing tumors [2] Group 2: Financial Performance - Evercore ISI has maintained an "Outperform" rating for CRNX, raising the price target from $80 to $90, despite the stock price being $52.57 and a negative price-to-earnings (P/E) ratio of -10.29 [3] - The company has a high price-to-sales ratio of 2,856.31 and an elevated enterprise value to sales ratio of 2,816.08, indicating that investors are paying a premium for its sales [4] - Crinetics has a negative earnings yield of -9.72%, but maintains a low debt-to-equity ratio of 0.046, reflecting minimal reliance on debt [5] - The company exhibits a strong liquidity position with a current ratio of 15.12, indicating it can comfortably cover its short-term liabilities [5]

Group 1 - Crinetics Pharmaceuticals will host a conference call and webcast on January 5, 2026, to provide updates on PALSONIFY™ commercialization and disclose topline results from the Phase 2 trial of atumelnant [1][2] - PALSONIFY™ (paltusotine) is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Crinetics has a deep pipeline of over 10 disclosed programs, including atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors [4] Group 2 - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3]

Core Insights - Crinetics Pharmaceuticals, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. Pacific Time [1] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [4] - The company has a deep pipeline of over 10 disclosed programs, including late-stage candidates such as atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors and other solid tumors [4] - Additional discovery programs target various endocrine conditions, including neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 39,575 shares in stock options and 26,525 RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have not responded adequately to surgery [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors, with a pipeline that includes over 10 disclosed programs targeting various endocrine conditions [4]

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to 20 new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 78,975 shares in stock options and 54,475 shares in RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have had inadequate surgical responses or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [4] - Crinetics has a deep pipeline with over 10 disclosed programs, including atumelnant, which is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Other discovery programs target various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]